메뉴 건너뛰기




Volumn 13, Issue , 2012, Pages

Efficiency and effectiveness of the use of an acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolic disease initiating oral anticoagulation: Study protocol for a randomized controlled trial

Author keywords

Acenocoumarol; Hematology; Pharmacogenetic

Indexed keywords

ACENOCOUMAROL; APOLIPOPROTEIN E; COMPLEX 1 OF THE VITAMIN K EPOXIDE REDUCTASE; CYTOCHROME P450; CYTOCHROME P450 2C9; CYTOCHROME P450 4 F2; LOW MOLECULAR WEIGHT HEPARIN; OXIDOREDUCTASE; UNCLASSIFIED DRUG;

EID: 84870917949     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-13-239     Document Type: Article
Times cited : (17)

References (40)
  • 1
    • 49549107264 scopus 로고    scopus 로고
    • Pharmacogenetics of oral anticoagulants: a basis for dose individualization
    • 10.2165/00003088-200847090-00002, 18698879
    • Stehle S, Kirchheiner J, Lazar A, Fuhr U. Pharmacogenetics of oral anticoagulants: a basis for dose individualization. Clin Pharmacokinet 2008, 47(9):565-594. 10.2165/00003088-200847090-00002, 18698879.
    • (2008) Clin Pharmacokinet , vol.47 , Issue.9 , pp. 565-594
    • Stehle, S.1    Kirchheiner, J.2    Lazar, A.3    Fuhr, U.4
  • 2
    • 15844427401 scopus 로고    scopus 로고
    • Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT) Italian Study on Complications of Oral Anticoagulant Therapy
    • 10.1016/S0140-6736(96)01109-9, 8709780
    • Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Musolesi S. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT) Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996, 348(9025):423-428. 10.1016/S0140-6736(96)01109-9, 8709780.
    • (1996) Lancet , vol.348 , Issue.9025 , pp. 423-428
    • Palareti, G.1    Leali, N.2    Coccheri, S.3    Poggi, M.4    Manotti, C.5    D'Angelo, A.6    Pengo, V.7    Erba, N.8    Moia, M.9    Ciavarella, N.10    Devoto, G.11    Berrettini, M.12    Musolesi, S.13
  • 3
    • 0027291892 scopus 로고
    • Bleeding complications in oral anticoagulant therapy: an analysis of risk factors
    • 10.1001/archinte.1993.00410130073007, 8323419
    • van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briët E. Bleeding complications in oral anticoagulant therapy: an analysis of risk factors. Arch Intern Med 1993, 153(13):1557-1562. 10.1001/archinte.1993.00410130073007, 8323419.
    • (1993) Arch Intern Med , vol.153 , Issue.13 , pp. 1557-1562
    • van der Meer, F.J.1    Rosendaal, F.R.2    Vandenbroucke, J.P.3    Briët, E.4
  • 5
    • 55449133425 scopus 로고    scopus 로고
    • Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy
    • 10.2217/14622416.9.9.1237, 18781852
    • Spreafico M, Lodigiani C, van Leeuwen Y, Pizzotti D, Rota LL, Rosendaal F, Mannucci PM, Peyvandi F. Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy. Pharmacogenomics 2008, 9(9):1237-1250. 10.2217/14622416.9.9.1237, 18781852.
    • (2008) Pharmacogenomics , vol.9 , Issue.9 , pp. 1237-1250
    • Spreafico, M.1    Lodigiani, C.2    van Leeuwen, Y.3    Pizzotti, D.4    Rota, L.L.5    Rosendaal, F.6    Mannucci, P.M.7    Peyvandi, F.8
  • 6
    • 62649171092 scopus 로고    scopus 로고
    • Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period
    • 10.1038/clpt.2008.294, 19225451
    • Teichert M, van Schaik RH, Hofman A, Uitterlinden AG, de Smet PA, Stricker BH, Visser LE. Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period. Clin Pharmacol Ther 2009, 85(4):379-386. 10.1038/clpt.2008.294, 19225451.
    • (2009) Clin Pharmacol Ther , vol.85 , Issue.4 , pp. 379-386
    • Teichert, M.1    van Schaik, R.H.2    Hofman, A.3    Uitterlinden, A.G.4    de Smet, P.A.5    Stricker, B.H.6    Visser, L.E.7
  • 7
    • 66549110050 scopus 로고    scopus 로고
    • Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy
    • 10.1182/blood-2008-09-176222, 19270263
    • Pérez-Andreu V, Roldán V, Antón AI, García-Barberá N, Corral J, Vicente V, González-Conejero R. Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood 2009, 113(20):4977-4979. 10.1182/blood-2008-09-176222, 19270263.
    • (2009) Blood , vol.113 , Issue.20 , pp. 4977-4979
    • Pérez-Andreu, V.1    Roldán, V.2    Antón, A.I.3    García-Barberá, N.4    Corral, J.5    Vicente, V.6    González-Conejero, R.7
  • 13
    • 36549030324 scopus 로고    scopus 로고
    • Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation
    • 10.1161/CIRCULATIONAHA.107.737312, 17989110, Couma-Gen Investigators
    • Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, Nicholas ZP, Kahn SF, May HT, Samuelson KM, Muhlestein JB, Carlquist JF, . Couma-Gen Investigators Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 2007, 116(22):2563-2570. 10.1161/CIRCULATIONAHA.107.737312, 17989110, Couma-Gen Investigators.
    • (2007) Circulation , vol.116 , Issue.22 , pp. 2563-2570
    • Anderson, J.L.1    Horne, B.D.2    Stevens, S.M.3    Grove, A.S.4    Barton, S.5    Nicholas, Z.P.6    Kahn, S.F.7    May, H.T.8    Samuelson, K.M.9    Muhlestein, J.B.10    Carlquist, J.F.11
  • 15
    • 23044440450 scopus 로고    scopus 로고
    • The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen
    • 10.1182/blood-2005-03-1108, 15947090
    • Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005, 106(7):2329-2333. 10.1182/blood-2005-03-1108, 15947090.
    • (2005) Blood , vol.106 , Issue.7 , pp. 2329-2333
    • Sconce, E.A.1    Khan, T.I.2    Wynne, H.A.3    Avery, P.4    Monkhouse, L.5    King, B.P.6    Wood, P.7    Kesteven, P.8    Daly, A.K.9    Kamali, F.10
  • 16
    • 34548096907 scopus 로고    scopus 로고
    • Use of genetic and nongenetic factors in warfarin dosing algorithms
    • 10.2217/14622416.8.7.851, 18240910
    • Wu AH. Use of genetic and nongenetic factors in warfarin dosing algorithms. Pharmacogenomics 2007, 8(7):851-861. 10.2217/14622416.8.7.851, 18240910.
    • (2007) Pharmacogenomics , vol.8 , Issue.7 , pp. 851-861
    • Wu, A.H.1
  • 19
    • 79851502859 scopus 로고    scopus 로고
    • A prospective study of an aggressive warfarin dosing algorithm to reach and maintain INR 2 to 3 after heart valve surgery
    • Meijer K, Kim YK, Carter D, Schulman S. A prospective study of an aggressive warfarin dosing algorithm to reach and maintain INR 2 to 3 after heart valve surgery. Thromb Haemost 2011, 105(2):232-238.
    • (2011) Thromb Haemost , vol.105 , Issue.2 , pp. 232-238
    • Meijer, K.1    Kim, Y.K.2    Carter, D.3    Schulman, S.4
  • 21
    • 79953331201 scopus 로고    scopus 로고
    • Predicting the warfarin maintenance dose in elderly inpatients at treatment initiation: accuracy of dosing algorithms incorporating or not VKORC1/CYP2C9 genotypes
    • 10.1111/j.1538-7836.2011.04213.x, 21255252
    • Moreau C, Pautas E, Gouin-Thibault I, Golmard JL, Mahé I, Mulot C, Loriot MA, Siguret V. Predicting the warfarin maintenance dose in elderly inpatients at treatment initiation: accuracy of dosing algorithms incorporating or not VKORC1/CYP2C9 genotypes. J Thromb Haemost 2011, 9(4):711-718. 10.1111/j.1538-7836.2011.04213.x, 21255252.
    • (2011) J Thromb Haemost , vol.9 , Issue.4 , pp. 711-718
    • Moreau, C.1    Pautas, E.2    Gouin-Thibault, I.3    Golmard, J.L.4    Mahé, I.5    Mulot, C.6    Loriot, M.A.7    Siguret, V.8
  • 23
    • 77955293789 scopus 로고    scopus 로고
    • A novel, single algorithm approach to predict acenocoumarol dose based on CYP2C9 and VKORC1 allele variants
    • 10.1371/journal.pone.0011210, 2887839, 20585445
    • Verde Z, Ruiz JR, Santiago C, Valle B, Bandrés F, Calvo E, Lucía A, Gómez Gallego F. A novel, single algorithm approach to predict acenocoumarol dose based on CYP2C9 and VKORC1 allele variants. PLoS One 2010, 5(6):e11210. 10.1371/journal.pone.0011210, 2887839, 20585445.
    • (2010) PLoS One , vol.5 , Issue.6
    • Verde, Z.1    Ruiz, J.R.2    Santiago, C.3    Valle, B.4    Bandrés, F.5    Calvo, E.6    Lucía, A.7    Gómez Gallego, F.8
  • 24
    • 80051512500 scopus 로고    scopus 로고
    • Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data
    • 10.1093/eurheartj/ehr116, 21636598, for the EU-PACT Study Group
    • Van Schie RM, Wessels JA, le Cessie S, de Boer A, Schalekamp T, van der Meer FJ, Verhoef TI, van Meegen E, Rosendaal FR, der Zee AH M-V, . for the EU-PACT Study Group Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. Eur Heart J 2011, 32(15):1909-1917. 10.1093/eurheartj/ehr116, 21636598, for the EU-PACT Study Group.
    • (2011) Eur Heart J , vol.32 , Issue.15 , pp. 1909-1917
    • Van Schie, R.M.1    Wessels, J.A.2    le Cessie, S.3    de Boer, A.4    Schalekamp, T.5    van der Meer, F.J.6    Verhoef, T.I.7    van Meegen, E.8    Rosendaal, F.R.9    der Zee, A.H.M.-V.10
  • 25
    • 84864103206 scopus 로고    scopus 로고
    • An acenocoumarol dosing algorithm using clinical and pharmacogenetic data in Spanish patients with thromboembolic disease
    • 10.1371/journal.pone.0041360, 3401172, 22911785
    • Borobia AM, Lubomirov R, Ramírez E, Lorenzo A, Campos A, et al. An acenocoumarol dosing algorithm using clinical and pharmacogenetic data in Spanish patients with thromboembolic disease. PLoS One 2012, 7(7):e41360. 10.1371/journal.pone.0041360, 3401172, 22911785.
    • (2012) PLoS One , vol.7 , Issue.7
    • Borobia, A.M.1    Lubomirov, R.2    Ramírez, E.3    Lorenzo, A.4    Campos, A.5
  • 27
  • 28
    • 84872375978 scopus 로고    scopus 로고
    • A multiplex assay to detect variations in the CYP2C9, VKORC1, CYP4F2 and APOE genes involved in acenocoumarol metabolism
    • pii: S0009-9120[12]00463-8
    • López-Parra AM, Borobia AM, Baeza C, Arroyo-Pardo E, Carcas AJ. A multiplex assay to detect variations in the CYP2C9, VKORC1, CYP4F2 and APOE genes involved in acenocoumarol metabolism. Clin Biochem 2012, pii: S0009-9120[12]00463-8.
    • (2012) Clin Biochem
    • López-Parra, A.M.1    Borobia, A.M.2    Baeza, C.3    Arroyo-Pardo, E.4    Carcas, A.J.5
  • 29
    • 23044505564 scopus 로고    scopus 로고
    • Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients
    • 10.1111/j.1538-7836.2005.01204.x, 15842354
    • Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005, 3(4):692-694. 10.1111/j.1538-7836.2005.01204.x, 15842354.
    • (2005) J Thromb Haemost , vol.3 , Issue.4 , pp. 692-694
    • Schulman, S.1    Kearon, C.2
  • 31
    • 39449086981 scopus 로고    scopus 로고
    • CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study
    • 10.1038/sj.clpt.6100316, 17851566
    • Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther 2008, 83(3):460-470. 10.1038/sj.clpt.6100316, 17851566.
    • (2008) Clin Pharmacol Ther , vol.83 , Issue.3 , pp. 460-470
    • Caraco, Y.1    Blotnick, S.2    Muszkat, M.3
  • 32
    • 51449102801 scopus 로고    scopus 로고
    • Venous thromboembolism in Spain. Comparison between an administrative database and the RIETE registry
    • 10.1016/j.ejim.2007.06.026, 18848178, RIETE Investigators
    • Guijarro R, Montes J, Sanromán C, Monreal M, . RIETE Investigators Venous thromboembolism in Spain. Comparison between an administrative database and the RIETE registry. Eur J Intern Med 2008, 19(6):443-446. 10.1016/j.ejim.2007.06.026, 18848178, RIETE Investigators.
    • (2008) Eur J Intern Med , vol.19 , Issue.6 , pp. 443-446
    • Guijarro, R.1    Montes, J.2    Sanromán, C.3    Monreal, M.4
  • 33
    • 34447136188 scopus 로고    scopus 로고
    • Recurrent venous thromboembolism during coumarin therapy. Data from the computerized registry of patients with venous thromboembolism
    • and the RIETE Investigators
    • Lobo JL, Jiménez D, Orue MT, Grau E, Naufall D, Madridano O, Monreal M, . and the RIETE Investigators Recurrent venous thromboembolism during coumarin therapy. Data from the computerized registry of patients with venous thromboembolism. Brit J Haematol 2007, 138(3):400-403. and the RIETE Investigators.
    • (2007) Brit J Haematol , vol.138 , Issue.3 , pp. 400-403
    • Lobo, J.L.1    Jiménez, D.2    Orue, M.T.3    Grau, E.4    Naufall, D.5    Madridano, O.6    Monreal, M.7
  • 34
    • 0033599765 scopus 로고    scopus 로고
    • Acute pulmonary embolism: clinical outcomes in the Internacional Cooperative Pulmonary Embolism Registry (ICOPER)
    • 10.1016/S0140-6736(98)07534-5, 10227218
    • Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the Internacional Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999, 353:1386-9.2. 10.1016/S0140-6736(98)07534-5, 10227218.
    • (1999) Lancet , vol.353
    • Goldhaber, S.Z.1    Visani, L.2    De Rosa, M.3
  • 35
    • 0037704209 scopus 로고    scopus 로고
    • Natural history of venous thromboembolism
    • I-22-I-30, 3
    • Kearon C. Natural history of venous thromboembolism. Circulation 2003, 107:I-22-I-30. 3.
    • (2003) Circulation , vol.107
    • Kearon, C.1
  • 36
    • 55549148457 scopus 로고    scopus 로고
    • Clinical outcome of patients with major bleeding after venous thromboembolism. Findings from the RIETE Registry
    • for the RIETE Investigators
    • Nieto JA, Cámara T, Gonzalez-Higueras E, Ruiz-Gimenez N, Guijarro R, Marchena PJ, Monreal M, . for the RIETE Investigators Clinical outcome of patients with major bleeding after venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008, 100(5):789-796. for the RIETE Investigators.
    • (2008) Thromb Haemost , vol.100 , Issue.5 , pp. 789-796
    • Nieto, J.A.1    Cámara, T.2    Gonzalez-Higueras, E.3    Ruiz-Gimenez, N.4    Guijarro, R.5    Marchena, P.J.6    Monreal, M.7
  • 37
    • 33847006936 scopus 로고    scopus 로고
    • Comparison of Outcomes Among Patients Randomized to Warfarin Therapy According to Anticoagulant Control Results From SPORTIF III and V
    • 10.1001/archinte.167.3.239, 17296878
    • White HD, Michael G, Jan F, Scott K, Hung-Fat T, Steen H, Albers GW. Comparison of Outcomes Among Patients Randomized to Warfarin Therapy According to Anticoagulant Control Results From SPORTIF III and V. Arch Intern Med 2007, 167:239-245. 10.1001/archinte.167.3.239, 17296878.
    • (2007) Arch Intern Med , vol.167 , pp. 239-245
    • White, H.D.1    Michael, G.2    Jan, F.3    Scott, K.4    Hung-Fat, T.5    Steen, H.6    Albers, G.W.7
  • 38
    • 57149140461 scopus 로고    scopus 로고
    • Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range
    • 10.1161/CIRCULATIONAHA.107.750000, 18955670, ACTIVE W Investigators
    • Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, Healey JS, Yusuf S, . ACTIVE W Investigators Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008, 118(20):2029-2037. 10.1161/CIRCULATIONAHA.107.750000, 18955670, ACTIVE W Investigators.
    • (2008) Circulation , vol.118 , Issue.20 , pp. 2029-2037
    • Connolly, S.J.1    Pogue, J.2    Eikelboom, J.3    Flaker, G.4    Commerford, P.5    Franzosi, M.G.6    Healey, J.S.7    Yusuf, S.8
  • 39
    • 34249863576 scopus 로고    scopus 로고
    • Frequency of adverse events in patients with poor anticoagulation: a meta-analysis
    • 10.1503/cmaj.061523, 1867836, 17515585
    • Oake N, Fergusson DA, Forster AJ, van Walraven C. Frequency of adverse events in patients with poor anticoagulation: a meta-analysis. CMAJ 2007, 176(11):1589-1594. 10.1503/cmaj.061523, 1867836, 17515585.
    • (2007) CMAJ , vol.176 , Issue.11 , pp. 1589-1594
    • Oake, N.1    Fergusson, D.A.2    Forster, A.J.3    van Walraven, C.4
  • 40
    • 23844524855 scopus 로고    scopus 로고
    • Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome
    • 10.1111/j.1538-7836.2005.01333.x, 15869588
    • van Dongen CJ, Prandoni P, Frulla M, Marchiori A, Prins MH, Hutten BA. Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome. J Thromb Haemost 2005, 3(5):939-942. 10.1111/j.1538-7836.2005.01333.x, 15869588.
    • (2005) J Thromb Haemost , vol.3 , Issue.5 , pp. 939-942
    • van Dongen, C.J.1    Prandoni, P.2    Frulla, M.3    Marchiori, A.4    Prins, M.H.5    Hutten, B.A.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.